158 related articles for article (PubMed ID: 19499180)
21. [A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review].
Adam Z; Matýková M; Krejcí M; Pour L; Kissová J; Slechtová M; Chlupová G; Stavarová Y; Simonides J; Penka M; Mayer J; Hájek R
Vnitr Lek; 2010 Jan; 56(1):67-78. PubMed ID: 20184115
[TBL] [Abstract][Full Text] [Related]
22. [Improvement of hepatomegaly after treatment with autologous hematopoietic stem cell transplantation followed by bortezomib and dexamethasone in Bence-Jones protein κ-type of multiple myeloma with systemic amyloidosis].
Nagamachi Y; Yamauchi N; Muramatsu H; Miyajima N; Inomata H; Okamoto T; Nozawa E; Gotoh Y; Koyama R; Ihara K; Nishisato T; Kato J
Rinsho Ketsueki; 2015 Mar; 56(3):323-8. PubMed ID: 25876787
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of intensive chemotherapy in AL amyloidosis: usefulness of flow cytometric analysis of plasma cells in bone marrow.
Matsuda M; Gono T; Shimojima Y; Sakashita K; Koike K; Ikeda S
Amyloid; 2003 Dec; 10(4):250-6. PubMed ID: 14986484
[TBL] [Abstract][Full Text] [Related]
24. [Heart transplantation and the subsequent treatment of AL amyloidosis].
Adam Z; Krejčí J; Krejčí M; Němec P; Spinarová L; Zampachová V; Cermáková Z; Pika T; Pour L; Kořístek Z; Tomíška M; Szturz P; Král Z; Mayer J
Vnitr Lek; 2013 Feb; 59(2):136-47. PubMed ID: 23461404
[TBL] [Abstract][Full Text] [Related]
25. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
[TBL] [Abstract][Full Text] [Related]
26. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
[TBL] [Abstract][Full Text] [Related]
27. AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation.
van Gameren II; Hazenberg BP; Jager PL; Smit JW; Vellenga E
Amyloid; 2002 Sep; 9(3):165-74. PubMed ID: 12408679
[TBL] [Abstract][Full Text] [Related]
28. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.
Comenzo RL; Vosburgh E; Simms RW; Bergethon P; Sarnacki D; Finn K; Dubrey S; Faller DV; Wright DG; Falk RH; Skinner M
Blood; 1996 Oct; 88(7):2801-6. PubMed ID: 8839879
[TBL] [Abstract][Full Text] [Related]
29. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.
Comenzo RL; Vosburgh E; Falk RH; Sanchorawala V; Reisinger J; Dubrey S; Dember LM; Berk JL; Akpek G; LaValley M; O'hara C; Arkin CF; Wright DG; Skinner M
Blood; 1998 May; 91(10):3662-70. PubMed ID: 9573002
[TBL] [Abstract][Full Text] [Related]
30. No regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvement.
Zeier M; Perz J; Linke RP; Donini U; Waldherr R; Andrassy K; Ho AD; Goldschmidt H
Nephrol Dial Transplant; 2003 Dec; 18(12):2644-7. PubMed ID: 14605290
[TBL] [Abstract][Full Text] [Related]
31. Nephrotic syndrome due to primary systemic AL amyloidosis, successfully treated with VAD (vincristine, doxorubicin and dexamethasone) alone.
Matsuda M; Gono T; Katoh N; Yoshida T; Tazawa K; Shimojima Y; Ishii W; Fushimi T; Ikeda S
Intern Med; 2008; 47(6):543-9. PubMed ID: 18344643
[TBL] [Abstract][Full Text] [Related]
32. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
[TBL] [Abstract][Full Text] [Related]
33. Diagnosis and treatment of AL amyloidosis.
Sezer O; Eucker J; Jakob C; Possinger K
Clin Nephrol; 2000 Jun; 53(6):417-23. PubMed ID: 10879660
[TBL] [Abstract][Full Text] [Related]
34. [A case of systemic amyloidosis treated by chemotherapy with autologous peripheral blood stem cell transplantation].
Mito A; Daga H; Ohashi N; Akita S; Shiomi K; Arita K; Fujiwara M; Asaoku H
Nihon Kokyuki Gakkai Zasshi; 2006 Aug; 44(8):583-8. PubMed ID: 16972617
[TBL] [Abstract][Full Text] [Related]
35. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
[TBL] [Abstract][Full Text] [Related]
36. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease.
Dember LM; Sanchorawala V; Seldin DC; Wright DG; LaValley M; Berk JL; Falk RH; Skinner M
Ann Intern Med; 2001 May; 134(9 Pt 1):746-53. PubMed ID: 11329232
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion.
Breems DA; Sonneveld P; de Man RA; Leebeek FW
Eur J Haematol; 2004 Mar; 72(3):181-5. PubMed ID: 14962236
[TBL] [Abstract][Full Text] [Related]
38. A rare lung nodule consisting of adenocarcinoma and amyloid deposition in a patient with primary systemic AL amyloidosis.
Miyazaki D; Yazaki M; Ishii W; Matsuda M; Hoshii Y; Nara K; Nakayama J; Ikeda S
Intern Med; 2011; 50(3):243-6. PubMed ID: 21297328
[TBL] [Abstract][Full Text] [Related]
39. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
Lokhorst HM; Sonneveld P; Cornelissen JJ; Joosten P; van Marwijk Kooy M; Meinema J; Nieuwenhuis HK; van Oers MH; Richel DJ; Segeren CN; Veth G; Verdonck LF; Wijermans PW
Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574
[TBL] [Abstract][Full Text] [Related]
40. [White blood cell lysis syndrome after autologous peripheral blood stem cell transplantation in the treatment of renal AL amyloidosis. Case report].
Gatica A; Bertin P; Tagle R
Rev Med Chil; 2006 Jun; 134(6):763-6. PubMed ID: 17130952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
